Study of the Value of Trio Exome Sequencing in the Etiological Assessment of Specific Non-syndromic Language and Learning Disorders (TSLA ES)

Specific language and learning disorders (SLLD) affect around 5-10% of school-aged children, or 1-2 child(ren) per class. SLLDs correspond to the impairment of a specific cognitive function and are divided into 5 categories: dyslexia, dysphasia, dyspraxia, dyscalculia and attention deficit hyperactivity disorder (ADHD) (DSM-5). In recent years, real progress has been made in their clinical diagnosis and management, thanks to a better description of these disorders in the DSM-5 and the advent of rehabilitative treatments (neuropsychology, speech therapy, occupational therapy, orthoptics, etc.). SLLD can occur in a sporadic or familial context (sibling involvement, a symptomatic parent, other relatives who may mimic dominant inheritance with variable expressivity and incomplete penetrance).

It has long been suspected that SLLD is secondary to multifactorial inheritance, with a combination of frequent genetic variations and environmental factors. In France, in the absence of an obvious syndromic diagnosis, the current strategy is to prescribe array CGH, combined in girls with a search for fragile X syndrome (in boys, this syndrome leads to systematic intellectual disability, which does not justify its study in SLLD). A few genes have been described as being specifically involved in a small proportion of SLLD, most often with de novo variations or inherited from a symptomatic parent. There are no distinctive clinical features to guide targeted sequencing of these genes. Moreover, our recent experience shows that genes implicated in intellectual disability may also be involved in SLLD. Very few studies have been published in the literature evaluating the value of exome sequencing in SLLD. Only two studies have been identified, involving 10 and 43 patients with specific SLLD.

In view of the roll-out of the French Genomic Medicine Plan (PFMG 2025), it is important to set up a study aimed at assessing the value of genome-wide sequencing in the etiological work-up for SLLD.

Participation in the study consists of:

• an inclusion visit, where an additional blood sample will be taken during the baseline work-up
• a results visit (4 months after the inclusion visit)

Optional qualitative study: semi-structured interview 1 year after the inclusion visit proposed to 20 patients or families with a positive result and to 10 patients with a negative result.

Study Overview

• Status: Recruiting
• Conditions: Specific Language and Learning Disorders (SLLD)
• Intervention / Treatment: Biological: Blood samples; Other: Consultation for results delivery; Other: Study Humanities and Social Sciences

• Study Type: Interventional
• Enrollment (Estimated): 101
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Julian DELANNE; Phone Number: 03 80 29 53 13; Email: julian.delanne@chu-dijon.fr

Study Locations

• France
  • Dijon, France
    • Recruiting
    • CHU Dijon Bourgogne
    • Contact: Eleonore VIORA DUPONT; Phone Number: 03 80 29 53 13; Email: eleonore.viora-dupont@chu-dijon.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Index case suffering from one or more severe learning disorders (requiring in-school help or intensive rehabilitation), justified by neuropsychological and/or speech therapy and/or occupational therapy assessments, reviewed by experts and supplemented if necessary within the framework of the study, and not yet having undergone genetic testing.
• Index case aged 3 to 40 years
• Sample may be taken from index case and 2 known biological parents
• Consent signed by the parents and by the index case if major
• Index case and parents covered by national health insurance

Exclusion Criteria:

• Index case and parents have a condition which, in the opinion of the investigator, would contraindicate the subject's participation in the study.
• Intellectual disability confirmed by neuropsychological testing or strongly suspected clinically in the index case and/or his/her parents
• Obvious syndromic diagnosis (syndrome or antecedents having definitely led to a developmental disorder)
• Persons deprived of liberty by judicial or administrative decision,
• Adults under guardianship,
• Persons residing in a health or social establishment
• Patients in critical situations
• Pregnant, parturient or nursing women
• Previous array CGH and/or Fragile X testing or any other targeted genetic examination (except standard karyotype).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Identification of a genetic cause defined by the presence of at least one ACMG class 4 or 5 variant.	Through study completion, an average of 4 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): August 7, 2023
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: July 3, 2023
• First Submitted That Met QC Criteria: July 3, 2023
• First Posted (Actual): July 11, 2023

Study Record Updates

• Last Update Posted (Actual): June 17, 2025
• Last Update Submitted That Met QC Criteria: June 13, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Mental Disorders; Neurobehavioral Manifestations; Neurodevelopmental Disorders; Communication Disorders; Learning Disabilities
• Other Study ID Numbers: DELANNE PHRCI 2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No